Denosumab

A denosumab biosimilar candidate demonstrated noninferior efficacy to its reference product, with similar safety profile, in postmenopausal patients with osteoporosis, according to data published in Arthritis Research & Therapy.

Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ibandronate as a sequential treatment after 12 months of romosozumab therapy, according to study findings published in Bone.

Postmenopausal women assigned denosumab have increases in mineral to matrix ratio at the cortical and cancellous bone at 2 to 3 years, but changes were not observed beyond 5 years, according to study findings.

Adults with osteoporosis have a higher risk for developing osteonecrosis of the jaw with denosumab therapy compared with bisphosphonates, according to study findings published in the Journal of Bone and Mineral Research.

The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now the second most used medication after alendronate, according to data presented at the ENDO annual meeting.

Following short-term therapy with teriparatide plus denosumab with a single dose of zoledronic acid may prevent bone loss associated with denosumab cessation among postmenopausal women, according to a study published in the Journal of Bone and Mineral Research.

Osteoporosis, long considered a disease of older age, is estimated to affect about 25% of women aged at least 65 years, according to the CDC.

Among patients using long-term glucocorticoids, denosumab is superior to alendronate in increasing bone mineral density in the spine after 1 year, according to a speaker at ACR Convergence 2020.

Women with osteoporosis who received romosozumab experienced the greatest gains in bone formation when the drug was administered before antiresorptive therapy, according to a speaker.

A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral density after 15 months of overlapping teriparatide and denosumab therapy, according to a speaker.